Ultrasound-guided trans-rectal high-intensity focused ultrasound (HIFU) for advanced cervical cancer ablation is feasible: a case report

Journal of Therapeutic Ultrasound

P. Abel⁵  W. Gedroyc⁴  L. Monzon¹  P. Price⁵  H. Wasan²  M. Chen²  E. Park²  E. Leen⁶  H. Ahmed³  M. Abel⁵ 

[1] Department of Radiology, Guy’s and St Thomas’ Hospital NHS Trust, St Thomas’ Hospital, Westminster Bridge Road, London SE1 7EH, UK;Department of Oncology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK;Department of Urology, University College Hospital, 235 Euston Road, London NW1 2BU, UK;Department of Radiology, Imperial College London, St Mary’s Hospital, Praed Street, London W2 1NY, UK;Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK;Department of Radiology, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK

关键词: HIFU;    FUS;    Ultrasound;    Focused;    Intensity;    Gynaecology;    Cervical;    Cancer;   

Others  :  1235024
DOI  :  10.1186/s40349-015-0043-6

 received in 2015-04-29, accepted in 2015-12-13,  发布年份 2015

【 摘 要 】

Introduction

High-intensity focused ultrasound (HIFU) is an ablative treatment undergoing assessment for the treatment of benign and malignant disease. We describe the first reported intracavitary HIFU ablation for recurrent, unresectable and symptomatic cervical cancer.

Case description

A 38 year old woman receiving palliative chemotherapy for metastatic cervical adenocarcinoma was offered ablative treatment from an intracavitary trans-rectal HIFU device (Sonablate® 500). Pre-treatment symptoms included vaginal bleeding and discharge that were sufficient to impede her quality of life. No peri-procedural adverse events occurred. Symptoms resolved completely immediately post-procedure, reappeared at 7 days, increasing to pre-procedural levels by day 30.

Discussion and evaluation

This first time experience of intracavitary cervical HIFU suggests that it is feasible for palliation of advanced cervical cancer, with no early evidence of unexpected toxicity. Ethical approval had also been granted for the use of per-vaginal access if appropriate. This route, alone or in combination with the rectal route, may provide increased accessibility in future patients with a redesigned device more suited to trans-vaginal ablations.

Conclusion

Intracavitary HIFU is a potentially safe procedure for the treatment of cervical cancer and able to provide symptomatic improvement in the palliative setting.

【 授权许可】

   
2015 Abel et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Tangjitgamol S, Katanyoo K, Laopaiboon M et al.. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev. 2014; 12:CD010401.
• [2]Malietzis G, Monzon L, Hand J et al.. High-intensity focused ultrasound: advances in technology and experimental trials support enhanced utility of focused ultrasound surgery in oncology. Br J Radiol. 2013; 86(1024):20130044.
• [3]Valerio M, Ahmed HU, Emberton M et al.. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2014; 66(4):732-51.
• [4]Machtinger R, Inbar Y, Ben-Baruch G et al.. MRgFUS for pain relief as palliative treatment in recurrent cervical carcinoma: a case report. Gynecol Oncol. 2008; 108(1):241-3.
• [5]Monzon L, Wasan H, Leen E et al.. Transrectal high-intensity focused ultrasonography is feasible as a new therapeutic option for advanced recurrent rectal cancer: report on the first case worldwide. Ann R Coll Surg Engl. 2011; 93(6):e119-21.
• [6]Ebbini ES, Ter Haar G. Ultrasound-guided therapeutic focused ultrasound: current status and future directions. Int J Hyperthermia. 2015; 31(2):77-89.